AAV Vector Delivery of Anti-HER2 Immunoglobulins for Brain Metastases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for breast cancer brain metastases are inadequate, as chemotherapeutic agents are excluded from the central nervous system by the blood-brain barrier, and existing therapies fail to effectively control metastatic dissemination of breast cancer into the CNS, leading to poor survival rates for patients.
Innovation Solution
An anti-neoplastic composition comprising an AAV vector formulated for delivery to the CNS, containing an expression cassette encoding an anti-neoplastic immunoglobulin product, such as an anti-Her2 antibody with disrupted binding for the neonatal Fc receptor, is administered intrathecally without disrupting the blood-brain barrier, allowing for targeted treatment of brain tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents are administered systemically, then they can treat breast cancer, but they are excluded from the CNS by the blood-brain barrier and cannot effectively treat brain metastases
Solution Approach 1:
The patent uses an adeno-associated virus (AAV) vector as an intermediary delivery system to transport anti-neoplastic immunoglobulin genes across the blood-brain barrier. The AAV vector serves as a mediator that enables CNS delivery without requiring disruption of the BBB, allowing the therapeutic immunoglobulins to be produced locally within the CNS to treat brain metastases
Solution Approach 2:
The invention enables the CNS to produce its own anti-neoplastic immunoglobulins through viral vector-mediated gene transfer. The local production of therapeutic antibodies within the CNS creates a self-sustaining treatment mechanism that continuously generates anti-cancer antibodies at the site of brain metastases without requiring repeated systemic administrations
2Reliability
If trastuzumab is injected directly into the CNS, then it can treat HER2-positive brain metastases, but the administration is complex and requires direct CNS injection
Solution Approach 1:
The patent replaces the mechanical approach of direct trastuzumab injection with a biological system - viral vector-mediated gene transfer. Instead of mechanically injecting pre-formed antibodies, the system uses AAV vectors to deliver genes that encode anti-HER2 immunoglobulins, allowing the body to produce the therapeutic antibodies endogenously. This substitution simplifies administration and enables sustained therapeutic production
Solution Approach 2:
The invention changes the fundamental parameter of treatment delivery from exogenous antibody administration to endogenous antibody production. By transferring the genetic blueprint for anti-HER2 antibodies into CNS cells via AAV vector, the system transforms the treatment from requiring repeated injections to establishing a self-renewing production system within the CNS
3Quantity of substance
If focused ultrasound bursts combined with microbubbles are used to permeabilize the blood-brain barrier, then trastuzumab can be delivered to the CNS, but the procedure requires physical disruption of the barrier
Solution Approach 1:
Instead of disrupting the blood-brain barrier to deliver trastuzumab, the invention inverts the approach by using AAV vectors to deliver genes that enable local production of anti-HER2 immunoglobulins within the CNS. This reverse strategy avoids barrier disruption entirely while achieving the same therapeutic goal of getting anti-cancer antibodies into the CNS
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively retards tumor growth, reduces tumor size, and increases progression-free survival in patients by delivering anti-neoplastic immunoglobulins directly to the CNS, as demonstrated by a 33% increase in median survival in mouse models with brain metastases.
Implementation Method 1
the AAV vector can be used to deliver the anti-neoplastic immunoglobulin gene product to the CNS by exploiting the transcytotic pathway
Data Source
AI summary
A composition comprising at least one AAV vector formulated for central nervous system delivery is described. The composition comprises at least one expression cassette which contains sequences encoding an anti-neoplastic immunoglobulin construct for delivery to the brain operably linked to expression control sequences therefor and a pharmaceutically acceptable carrier. The anti-neoplastic immunoglobulin construct may be an immunoglobulin modified to have decreased or no measurable affinity for neonatal Fc receptor (FcRn). Also provided are methods of using these constructs in preparing pharmaceutical compositions and uses thereof in anti-neoplastic regimens, particularly for primary and/or metastatic cancers of the brain.